Established in 2019, Commodore Capital operates as a venture capital investment firm headquartered in New York, New York. The firm specializes in venture capital investments within the healthcare sector, leveraging a science-driven approach. Commodore Capital strategically invests in innovative companies across the United States dedicated to developing medical products that enhance patients' lives. With a focus on long-term investments, Commodore Capital targets small-cap public and late-stage private biopharmaceutical companies.
Egen Atkinson serves as Co-Founder and Managing Partner at Commodore Capital. Before establishing Commodore, Egen gained valuable experience as a biotechnology investor on the public and crossover team at Venrock. Prior to his tenure at Venrock, he contributed to the launch and management of a Phase I clinical trial for Age-Related Macular Degeneration at ForSight Vision4 (later acquired by Roche). Additionally, Egen provided consultation on gene therapy pipeline development for Spark Therapeutics (subsequently acquired by Roche) prior to its IPO. Egen holds an MD from the Perelman School of Medicine at the University of Pennsylvania, where he graduated with honors as part of Alpha Omega Alpha and received the prestigious Spencer Morris Prize, awarded to the top graduating student in his class. He furthered his education with an MBA in Health Care Management from the Wharton School and earned an AB in Economics from Harvard University. During his time at Harvard, Egen showcased his leadership skills as co-captain of the NCAA Division I water polo team, where he played for four consecutive years.
Michael Kramarz serves as Co-Founder and Managing Partner at Commodore Capital. Before co-founding Commodore, Michael specialized in medical products investments at Samlyn Capital, focusing on small and mid-cap biopharma companies. During his graduate studies, Michael gained valuable experience at Celgene’s Cellular Therapeutics subsidiary (later acquired by Bristol Myers) and provided consulting services for Audentes Therapeutics (subsequently acquired by Astellas), where he contributed to the prioritization of gene therapy indication candidates before the company's IPO. Michael holds an MD from the Perelman School of Medicine at the University of Pennsylvania, graduating with honors as part of Alpha Omega Alpha and ranking in the top 5% of his class. He was awarded the prestigious James B. Couch Prize, recognizing the graduating student with the highest achievement in medicine and business. Additionally, Michael earned an MBA in Health Care Management from the Wharton School, where he was honored with a Kaiser Fellowship and graduated with Honors. He completed his undergraduate studies with distinction, graduating summa cum laude with a BSE in Biomedical Engineering from Duke University. Michael was also the recipient of the Leonardo da Vinci Award, presented to the top graduating student in his major.
Commodore Capital manages assets for 3 clients with discretionary assets under management (AUM) totaling $1,356,387,341 according to their Form ADV from March 2024. Their most recent 13F filing for Q4 2023 disclosed holdings of managed 13F securities valued at $1,144,464,541, with a top 10 holdings concentration of 62.98%. Notably, Commodore Capital's largest holding is Merus BV, with 4,747,373 shares held.
